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Leishmania infantum is the etiological agent of zoonotic visceral leishmaniasis in the Mediterranean basin.
The disease is fatal without treatment, which has been based on antimonial pentavalents for more than
60 years. Due to resistances, relapses and toxicity to current treatment, the development of new drugs is
required. The structure of the L. infantum tyrosine aminotransferase (LiTAT) has been recently solved
showing important differences with the mammalian orthologue. The characterization of LiTAT is reported
herein. This enzyme is cytoplasmic and is over-expressed in the more infective stages and nitric oxide
resistant parasites. Unlike the mammalian TAT, LiTAT is able to use ketomethiobutyrate as co-substrate.
The pharmacophore model of LiTAT with this speciﬁc co-substrate is described herein. This may allow the
identiﬁcation of new inhibitors present in the databases. All the data obtained support that LiTAT is a
good target candidate for the development of new anti-leishmanial drugs.
 2014 The Authors. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. This is
an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction their usefulness (Haldar et al., 2011). Therefore there is a needLeishmaniases are a group of parasitic diseases caused by spe-
cies of the genus Leishmania with an estimated annual incidence
of almost 1.8 million cases (WHO, 2012). Leishmania infantum (syn-
onym to L. chagasi, in the New World) (Kinetoplastida: Trypanoso-
matidae) is the etiological agent of zoonotic visceral leishmaniasis,
which is fatal without treatment. In the Mediterranean basin,
domestic dogs are the main reservoir of the parasite and an
increase in co-infection with HIV has been registered (Pasquau
et al., 2005). For over 60 years, pentavalent antimonials have been
the most important drugs for treatment of leishmaniases and are
still widely used. However, resistances against them have
increased over the years. Other drugs like amphotericin B, its lipid
formulations and miltefosine are effective against leishmaniasis,
but their high cost, toxicity and appearance of resistances limitfor ﬁnding new targets involved in pathogenic mechanisms and
infectivity of the parasite.
The dimorphic life cycle of the parasite alternates between a
mobile extracellular promastigote form in the phlebotomine insect
vector and an immobile intracellular amastigote form in the mam-
malian host (Handman, 2001). Once inside the gut of the vector,
promastigotes undergo a process of differentiation increasing their
infectivity prior to be inoculated into themammalian host complet-
ing the biological cycle. This process can be mimicked in culture,
where signiﬁcant differences in gene expression proﬁle between
logarithmic and stationary phases have been described (Alcolea
et al., 2010a). A minor subpopulation (about 1%) within the station-
ary phase does not agglutinate with peanut agglutinin (PNA) and
is more infective. Gene expression proﬁling carried out comparing
these parasite subpopulations showed a certain group of genes
up-regulated in the more infective PNA subpopulation (Alcolea
et al., 2009). One of these genes was the L. infantum tyrosine amino-
transferase (LiTAT) gene, which may play a key function in the par-
asite. In the genus Leishmania, metabolism of amino acids play an
important role throughout differentiation from promastigotes to
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where the main nutrients available are amino acids and lipids
(Rosenzweig et al., 2008). TAT deﬁciency leads to metabolic disease
in humans (Natt et al., 1987), whereas consequence of TAT altera-
tions in Leishmania are not well understood. Aromatic amino acid
catabolism consists of two steps in trypanosomatids. The ﬁrst one
is reversible transamination of aromatic amino acid to its corre-
sponding oxoacid (al-Hemidan and al-Hazzaa, 1995) and is cata-
lyzed by TAT. This broad speciﬁcity enzyme transfers the amino
group from the aromatic amino acids to an incoming oxoacid that
accepts it. The deaminated amino acid is then reduced by a dehy-
drogenase and the resulting product is supposed to be excreted.
This role has been related in other pathogenic trypanosomatids
with pathogenesis. As an example, depletion of certain amino acids
has been correlated with pathology of sleeping sickness, a disease
caused by Trypanosoma brucei (Seed et al., 1983). The lack of certain
amino acids in the host, such as tryptophan, would lead to the
shortage of essential metabolites for the host (Tizard et al., 1978;
Seed et al., 1983; Hall et al., 1985; Leelayoova et al., 1992). More-
over, the toxicity of end-products such as phenylpyruvate has been
related to the pathogeny of the disease (Stibbs and Seed, 1973).
These end-products of the aromatic amino acid oxidation process
were identiﬁed and detected in high amounts into the supernatant
of T. cruzi epimastigotes axenic culture (Montemartini et al., 1994a).
Broad substrate speciﬁcity aminotransferases have been associ-
ated to the methionine recycling pathway in trypanosomatids such
as T. brucei and Crithidia fasciculata, where this protein catalyzes
the last step of this pathway, the conversion of ketomethiobutyrate
(KMTB) to methionine via transamination (Berger et al., 1996,
2001). Methionine regeneration has been targeted as an important
pathway for anti-malarial and anti-T. brucei drug therapy based on
50-deoxy-50-(methylthio) adenosine analogues (Sufrin et al., 1995;
Goldberg et al., 1998). Additionally, as methionine is an essential
amino acid involved in a number of critical processes in fast grow-
ing cells, this pathway has been previously targeted for the devel-
opment of antiproliferative compounds (Quash et al., 2004).
LiTAT belongs to the Ic subfamily and is involved in tyrosine
metabolism. At present, just a few TAT structures have been
solved. The ﬁrst structure released corresponds to the trypanoso-
matid T. cruzi (TcTAT) (PDB code: 1BW0) (Blankenfeldt et al.,
1999), followed by the human (PDB code: 3DYD) and the mouse
TAT (PDB code: 3PDX) (Mehere et al., 2010). Recently, the structure
of LiTAT has been solved to 2.3 Å (PDB code: 4IX8) (Moreno et al.,
2014). On the basis of this background, the aim of the work is the
characterization of the protein regarding its cellular localization
and expression at the different stages as well as the excretion of
the ﬁnal product p-hydroxyphenyllactate (pHPL) to the culture
medium. Additionally we have studied structural differences found
not only with the mammalian enzyme but also with the other try-
panosomatid orthologue described so far. Structural comparison
and subsequent docking assays have led us to generate a prelimin-
ary pharmacophore using a speciﬁc substrate of LiTAT which will
help to identify inhibitors currently present in the databases. These
data support that this enzyme may be a good candidate for novel
structure-based development of drugs affecting the parasite but
not the mammalian host.2. Material and methods
2.1. Promastigote and axenic amastigote cultures
L. infantum isolate M/CAN/ES/98/10445 (zymodeme MON-1)
was cultured in RPMI 1640 supplemented with L-glutamine
(Thermo Fisher, Massachusetts, USA), 10% heat inactivated foetal
bovine serum (HIFBS) (Sigma) and 100 lg/ml streptomycin –100 IU/ml penicillin (Cambrex, Karlskoga, Sweden) (completemed-
ium) at 27 C and a starting density of 2  106 promastigotes/ml. L.
chagasi resistant (LBM/LVC/SE/30) and sensitive (LBM/LVC/SE/19)
strains to nitric oxide (NO) were kindly provided by R. Almeida
(Universidade Federal de Sergipe, Brazil). Experiments were per-
formed on three replicates and promastigotes were recovered in
early-logarithmic (day 2) and stationary phase (day 6). The aggluti-
nation procedure was carried out as previously described (Alcolea
et al., 2009). Brieﬂy, stationary phase promastigoteswere recovered
and harvested at 2000 g. Then, they were resuspended in complete
medium and incubated with 50 lg/ml PNA at a cell density of
2  108 (Sigma–Aldrich, Buchs, Switzerland) at room temperature
for 30 min. 108 promastigotes of each subpopulation (PNA+ and
PNA) were centrifuged and washed twice with 100 mM PBS pH
7.4. Axenically grown amastigote forms of L. infantum were
obtained at 37 C with 5% CO2 by weekly passages in Medium 199
(Sigma), 10% HIFBS (Sigma), 10 mM PBS pH 5.5 and 100 lg/ml
streptomycin – 100 IU/ml penicillin (Cambrex) from a inoculum
of 5  106 stationary promastigotes/ml. After that, 108 axenic
amastigotes obtained at a starting cell density of 5  106 were cen-
trifuged on day 4 and washed twice with 100 mM PBS pH 7.4.
2.2. Identiﬁcation of p-HPL
The extraction procedure was carried out as previously
described (Montemartini et al., 1994a) slightly modiﬁed. The neg-
ative control used was sterile complete medium. A total volume of
230 ml of cell-free culture medium was used in each extraction
(including the negative control). To summarize, pHPL was sepa-
rated by liquid chromatography on an Agilent 1200 HPLC system
equipped with a C18/5 lm 25  0.45 cm column and a diode array
detector. A discontinuous gradient of acetonitrile (10–30% ACN
6 min; 30% ACN 6–12 min; 30–100% ACN 12–19 min) was used
at 1 ml/min ﬂow rate. Commercially available pHPL (Sigma) was
used as standard. Subsequently, the eluted peak was derivatized
by trimethylsilylation and analyzed in a gas chromatography cou-
pled to mass spectrometry (GC–MS) Agilent 7980A-5975C system
equipped with an injector split-splitless Inlet (T = 320 C;
P = 12.5 psi) and an HP5 MS column 30 m  250 lm  0.25 lm
(polysiloxane). The mass spectrometer was set to register compo-
nents in a mass range between 40 and 500 g/mol. The sample
was diluted ﬁve times in water and the ﬁnal concentration of pHPL
in the culture medium was obtained by integrating the area under
the peak and interpolating it to four different concentrations of
pHPL standard (0.5, 0.1, 0.05 and 0.01 mM).
2.3. Determination of p-hydroxyphenylpyruvate dehydrogenase
activity in promastigotes
The determination of p-hydroxyphenylpyruvate (pHPP) reduc-
tion catalyzed by pHPP dehydrogenase was determined following
a previous report with some modiﬁcations (Montemartini et al.,
1994b) using commercial pHPP (SIGMA). The decrease of absor-
bance at 340 nm was measured spectrophotometrically at 27 C
in a Cary4000 system in the ﬁrst ﬁve minutes of the reaction.
Early-logarithmic, late-logarithmic and stationary phase prom-
astigotes were lysed mildly in Tris–HCL 50 mM pH 7.4, EDTA
2 mM and Triton X-100 0.2%. Protein extracts were quantiﬁed by
the Bradford method (Bradford, 1976) and 200 lg of total protein
extracts were used in each reaction. The ﬁnal value is the mean of
three replicates in two different cultures sampled in every phase.
2.4. Determination of recombinant LiTAT activity
LiTAT activity was assayed with KMTB by the method of Dia-
mondstone (Diamondstone, 1966) without the addition of diet-
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amount of LiTAT catalyzing the formation of 1 lmol of p-hydroxy-
phenylpyruvate. Four replicates were performed.
2.5. Western blot analysis
Cell extracts of L. infantum promastigotes were obtained as
described previously (Alcolea et al., 2011). A speciﬁc polyclonal
antibody against LiTAT was obtained with 2 mg of puriﬁed native
recombinant LiTAT as described (Moreno et al., 2014) in a New
Zealand rabbit. For this purpose it was administered in four weekly
subcutaneous shots together with the Freund’s Adjuvant. P. Mich-
els (University of Edinburgh, UK) kindly provided anti-L. mexicana
glycosomal glyceraldehyde 3-phosphate dehydrogenase (gGAPDH)
rabbit serum and a dilution of 1:10000 was used (Gualdron-Lopez
et al., 2013). Western blotting of the protein extracts was carried
out as described (Gonzalez-Aseguinolaza et al., 1997) using a
1:3000 dilution of primary antibody anti-LiTAT and 1:2000 dilu-
tion of HRP-conjugated anti-rabbit IgG secondary antibody (Dako,
Denmark). In all cases, 10 lg of total protein were loaded per well.
L. infantum and L. chagasi protein extracts were quantiﬁed as
described in Section 2.3.
2.6. Subcellular localization by immunoﬂuorescence
L. infantum early-logarithmic promastigotes (day 2) were laid
on the slides (2  105 each) and dried at room temperature.
The cells were ﬁxed for 5 min at room temperature in 4% parafor-
maldehyde. Then they were washed in PBS and permeabilized with
PBS-0.5% Triton X-100. Blocking was carried out with 5% skimmed
milk in PBS-0.1% Tween 20 at 37 C for 30 min in a wet chamber.
The coverslips were incubated with a 1:1000 dilution of the LiTAT
polyclonal antibody in blocking buffer for 1 h. After washing, the
slides were incubated with a 1:200 dilution of goat anti-rabbit
IgG conjugated with Alexa Fluor 488 (Life Technologies, USA) in
blocking buffer in darkness for 1 h. During the last 10 min of incu-
bation with the secondary antibody, coverslips were treated with
DAPI (Life Technologies) at a ﬁnal concentration of 0.2 lg/ml in
darkness. After washing, the coverslips were mounted on the slides
with Mowiol (Merck-Millipore, Germany) and observed in a confo-
cal microscope Leica TCS SP5, with a magniﬁcation of 630.
2.7. Subcellular localization by digitonin fractionation extractions
For digitonin treatment fresh early-log cells were harvested,
washed once in PBS, and resuspended in 20 mM Tris–HCL (pH
8.0), 1 mM EDTA, 1 mM DTT containing a protease inhibitor cock-
tail (Roche) at a cell density of 5  107 cells/ml. Aliquots of 100 ll
were made and supplemented with increasing (0–10 mg/mg of
total protein extracts) concentrations of digitonin (Roche) and
incubated at 26 C for 10 min. Cells were then centrifuged at
20,800g for 2 min. Supernatants were immediately removed and
resolved by 10% SDS–PAGE. Protein extracts quantiﬁcation and
Western blotting incubations were done as described above.
2.8. Molecular dynamics simulations
Complexes of LiTAT with the transition states containing tyro-
sine bonded to pyridoxal phosphate in its quinonoid resonance
form, pyridoxamine (PMP) and PMP with KMTB bonded (all of
them are described as transition states involved in transamina-
tion reaction) were obtained by molecular docking using the soft-
ware Discovery Studio 4.0 (Accelrys Software Inc., San Diego, CA.)
The molecules for docking were prepared by using Smi2Depict
tool to generate 2D images from SMILES (Chen et al., 2007). Input
site sphere of interaction without PLP ligand (coordinate in athree-dimensional system which can represent a single point or
the head of a vector whose tail is located at the origin: X,Y,Z,
Radius): 64.8412 Å, 15.5681 Å, 9.92923 Å, 18.7782 Å. Simulations
with the transition states were conducted with LiTAT using CDoc-
ker (Wu et al., 2003) as docking algorithm to predict binding
positions, conformations and orientations of the transition states
and the ligand KMTB. Default parameters were used for all the
simulations. The root mean square deviation (RMSD) values
derived from the docked transition states were obtained using
PLP bonded to LiTAT structure as the model to compare. The fea-
tures that match the interactions between KMTB and the protein
binding site with PMP have been used to build the pharmaco-
phore model. Each sphere deﬁnes the location tolerance of a par-
ticular feature point. The default radius tolerance for all features
is 1.6 Å.3. Results
3.1. The end-product of tyrosine catabolism is produced in high
amounts and excreted into the culture medium by promastigotes
The ether-soluble fraction extracted from three replicates of
stationary-phase promastigote culture allowed to detect different
peaks corresponding to excreted products from the parasite. The
peak depicted in Fig. 1A corresponds to p-hydroxyphenyllactic
(pHPL) standard, which elutes at 11.4 min. The supernatant of
the L. infantum culture was run and the chromatogram differs
greatly from the negative control (Fig. 1B and C). Among all peaks,
the one eluting at 10.7 min was isolated from the rest and then
analyzed by GC. The mass spectrum of the peak eluting at
13.68 min (Fig. 1D) was identical to the mass spectrum of the stan-
dard (Fig. 1E and F), which is indicative of the presence of pHPL in
the supernatant of L. infantum promastigotes. The ﬁnal concentra-
tion of pHPL in the culture medium is 3.39 mM. The activity of
pHPP dehydrogenase measured in different promastigote growth
phases is similar between early and mid-logarithmic stage,
however the activity is increased by two times at the stationary
phase (Table 1).
3.2. LiTAT is over-expressed in more infective promastigotes and in
resistant strains to nitric oxide
LiTAT protein expression was evaluated by Western blotting of
L. infantum cell extracts obtained from samples taken at different
growth phases. The protein was mainly expressed in promastig-
otes at the proliferative early-logarithmic stage whereas it was
almost absent at the stationary phase (Fig. 2A). However,
over-expression was observed in the more infective PNA
subpopulation compared to the PNA+ subpopulation within the
stationary phase (Fig. 2B). The protein was also over-expressed
in amastigote-like forms of L. infantum (Fig. 2A). Furthermore, in
early-logarithmic stage promastigotes a nitric oxide resistant
strain of L. chagasi TAT displayed a over-expression compared to
a NO sensitive strain (Fig. 2C).
3.3. Subcellular localization of TAT
LiTAT was detected by indirect immunoﬂuorescence (IFI) in L.
infantum promastigotes at different growth phases. The
distribution pattern of the protein is mainly cytoplasmic though
not homogenously distributed. By contrast, we were unable to
detect ﬂuorescence in the stationary phase promastigotes
(Fig. 3A). In order to assess cytoplasmic subcellular localization,
L. infantum promastigotes were incubated with increasing
digitonin concentrations to extract soluble and insoluble proteins
Fig. 1. pHPL is excreted in high amounts by L. infantum promastigotes. Figures A, B and C correspond to HPLC chromatograms. (A) 20 ll of a solution containing 0.5 mM pHPL
as standard was run. The peak corresponding to pHPL eluted at 11.14 min. (B) A total volume of 230 ml of complete medium was used to extract the ether soluble fraction as
control in order to asses that there are no peaks at the same elution time than the standard in the chromatogram. 20 ll was loaded in the run. (C) A total volume of 230 ml of
supernatant obtained from a stationary-phase promastigote culture was used to extract the ether-soluble fraction and analyzed by HPLC. The peak which its retention time is
similar to the retention time of the standard was eluted and sent for further analysis by GC–MS. (D) Gas chromatogram of the peak eluted in Fig. 1C. The major peak with an
elution time of 13.7 min was isolated and analyzed by mass spectrometry. (E and F) The mass spectrum of the peak (E) was identical to the mass spectrum of the pHPL
standard (F).
Table 1
p-hydroxyphenyl pyruvate dehydrogenase activity in different promastigote growth
phases.
Culture phase Speciﬁc activity (U/mg)
Early-logarithmic 8.16  103 ± 0.21  103
Mid-logarithmic 8.54  103 ± 0.43  103
Stationary 17.12  103 ± 0.38  103
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LiTAT was extracted to the supernatant at low concentrations of
digitonin (Fig. 3B). The gGAPDH used as a compartmentalized pro-
tein control was not released completely even at 10 mg digitonin
per mg of total protein. According to these results, LiTAT is mainly
cytoplasmic.Fig. 2. Expression proﬁle of LiTAT. In all cases a 1:3000 dilution and 1:10000 of
speciﬁc anti-LiTAT and anti-gGAPDH polyclonal antibody respectively was used.
10 lg of total protein extracts were loaded per well. (A) L. infantum early-
logarithmic and stationary phase promastigotes and axenic amastigotes protein
extracts. (B) L. infantum stationary PNA+ and PNA protein extracts. (C) L. chagasi
early-logarithmic stage of resistant and sensitive strains.3.4. Enzymatic activity and in silico studies
First, we determined the enzymatic activity of LiTAT protein
puriﬁed as reported (Moreno et al., 2014) with tyrosine as sub-
strate and KMTB as co-substrate (AEE = 33.4 ± 2 U/mg of puriﬁed
protein). The scheme of the KMTB transamination using tyrosine
as amino donor is shown in Fig. 4A. In order to identify the struc-
tural features involved in the recognition of KMTB, we performed
molecular docking simulations. The formation of the intermediate
state pyridoxamine phosphate (PMP) is preceded by a quinonoid
intermediate which is rapidly hydrolyzed to PMP (Kirsch et al.,
1984). We ﬁrst determined the disposition of the quinonoid inter-
mediate with tyrosine with the lowest free energy value, depicted
in Fig. 4B. The RMSD compared to the PLP in the 2.3 Å-solved struc-
ture of LiTAT, for that position is 2.53 Å. After that, the position
Fig. 3. Subcellular localization of LiTAT. (A) Confocal images were obtained using L. infantum early-logarithmic promastigotes and the green ﬂuorescence corresponds to the
Alexa Fluor 488 coupled to the primary antibodies speciﬁcally raised against the recombinant TAT. The blue ﬂuorescence corresponds to the nuclear (N) and kinetoplast (K)
DNA, stained with DAPI. LiTAT is distributed non-homogenously throughout the entire cytoplasm in early-logarithmic phase promastigotes. In stationary phase
promastigotes any green ﬂuorescence could be detected. (B) 10 lg of total protein extracts of selected fractions resulting from the digitonin gradient were subjected to
Western blot analysis and probed with speciﬁc polyclonal antibody anti-LiTAT and anti-L. mexicana gGAPDH. Digitonin gradient assay allowed suggesting that the protein is
cytoplasmic since the compartmentalized control protein (gGAPDH) is released to the supernatant with higher concentration of detergent than LiTAT as depicted in the
graphics. (For interpretation of the references to colours in this ﬁgure legend, the reader is referred to the web version of this paper.)
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106 poses for the PMP transit state. These poses were compared
with those of the quinonoid transit state, being the most similar
not the lowest in free energy value but the second one (RMSD is
3.6 and 1.19 Å, respectively), which is showed in Fig. 4C. The dis-
tance between the secondary amine of PMP transferred to the
acceptor (the oxoacid group of KMTB) is 3.89 Å. The docked KMTB
molecule allowed generating the pharmacophore group of LiTAT
with KMTB (Fig. 5A). The residues involved in the pharmacophore
and the distances between them are depicted in Fig. 5B.4. Discussion
Despite visceral leishmaniasis is the most severe form of the
disease and is fatal without treatment, the current therapy for
leishmaniasis is limited to a few drugs. The oldest and most used
in therapy against leishmaniasis is pentavalent antimonials. Never-
theless, the increase in resistances, relapses and patients who did
not respond to treatment (Ouakad et al., 2011) has caused the sub-
stitution of antimonials by other drugs like the oral formulation of
miltefosine (Thakur et al., 2009). However, resistances to this treat-
ment have been also reported (Cojean et al., 2012). Therefore, there
is a need for ﬁnding new leishmanicidal compounds. The identiﬁ-
cation of targets involved in metabolic pathways present in Leish-
mania but absent in the host is the ﬁrst step to ﬁnd new drug
targets. Differentiation of promastigotes transmitted by the sandﬂy to the mammalian host to amastigotes surviving inside phago-
cytes is a crucial process in the life cycle of the parasite. In the gut
of the vector, one of the most available sources of energy are amino
acids, which are normally oxidized and get into the TCA cycle,
obtaining NAD(P)+ (Rosenzweig et al., 2008). The availability of
nutrients is lower in the phagolysosome of the host cell
(McConville et al., 2007), where amastigotes scavenge essential
amino acids released by the proteolysis of host proteins (Antoine
et al., 1998). Therefore, the amino acid transporters systems, which
are essential, are over-expressed in the amastigote stage, suggest-
ing that catabolism of amino acids is highly activated (Alcolea
et al., 2010b; Landfear, 2011). Amino acid metabolism may be a
good option in searching for targets due to the differences between
mammals and trypanosomatids as it has been previously proposed
(Nowicki and Cazzulo, 2008). Consequently, catabolism of amino
acids might be relevant for infectivity and survival within the host
macrophage. Excretion of the end-products of the aromatic amino
acid catabolism was also reported in T. cruzi but it is remarkable
that certain aromatic products are not excreted in L. mexicana
(Montemartini et al., 1994a). It was proposed that the symptom-
atology of the African trypanosomiasis is partially due to excretion
of the end-products of aromatic amino acid catabolic pathways by
the parasite, highlighting the tryptophan catabolic pathway (Seed
et al., 1983). In this work, we have demonstrated that there is pHPP
dehydrogenase activity and that the aromatic 2-hydroxyacid
corresponding to tyrosine is being excreted in high amounts in L.
infantum and this can be related to the infectivity of the parasite
Fig. 4. Molecular docking simulation with transition states. (A) Scheme reaction of transamination catalyzed by LiTAT using tyrosine as amino donor and KMTB as amino
acceptor. (B) LiTAT with quinonoid form transit state complex. (C) LiTAT-PMP transition state complex. LiTAT protein is shown as a cyan cartoon. Lys286, which covalently
bonds PLP, and ligands are shown in balls and sticks and residues from LiTAT which bond KMTB molecule are shown by thin sticks colored by elements. Carbons, oxygens,
nitrogens and phosphates are shown by gray, red, blue and orange respectively. (For interpretation of the references to colours in this ﬁgure legend, the reader is referred to
the web version of this paper.)
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population was described suggesting that this increase may be
explained by the excretion of the end-product pHPL (Alcolea
et al., 2009). In fact, it is probably related with virulence in T. brucei
(Nowicki and Cazzulo, 2008). The over-expression of LiTAT has
been conﬁrmed at the protein level both in the more infective
PNA promastigote subpopulation (Fig. 2B) and in a resistant strain
of L. chagasi to nitric oxide, (Fig. 2C) which is one of the main mech-
anisms used by the host macrophage against the parasite. LiTAT is
also strongly over-expressed in the proliferating early logarithmic
phase, as well as in the amastigote stage. Conversely, the protein
almost completely disappears in the stationary phase (Fig. 2A).
The expression of LiTAT in more infective promastigotes suggests
that the enzyme has a relevant function during the process of pro-
mastigote pre-adaptation to the new host.
LiTAT in early-logarithmic promastigotes is almost entirely dis-
tributed along the cytoplasm in spite of appearing as non-homog-
enously distributed according to the IFI assays. The subcellular
fractionation experiment supports that the protein is cytoplasmic
as in L. major (Marciano et al., 2009) (Fig. 3). This subcellular local-
ization pattern can be advantageous in order to improve the access
of a putative inhibitor to the target once it crosses the plasma
membrane, which is an important requirement to consider the
protein as a good target (Myler, 2008).
The differences between LiTAT and the mammalian ortho-
logues both in sequence identity (Jensen and Gu, 1996) and in
the structure of the active center reﬂect their different substrate
speciﬁcity and activity (Mehere et al., 2010; Moreno et al.,
2014). This is probably critical for the recognition of substratesor analogues. Unlike in trypanosomatid TATs, the speciﬁcity of
the human is restricted to the substrate pair tyrosine/a-ketoglu-
tarate (Sivaraman and Kirsch, 2006). Although both LiTAT and
TcTAT are able to use pyruvate as amino acceptor, LiTAT does
not use a-ketoglutarate as the TcTAT and the mammalian TAT
do because of the absence of two important residues in the N-ter-
minal domain that are essential for the recognition of the dicar-
boxylic oxoacid (Sobrado et al., 2003; Moreno et al., 2014;). In
trypanosomatids such as T. brucei and C. fasciculata, the ﬁnal reac-
tion of the methionine regeneration pathway was identiﬁed to be
catalyzed by a broad substrate aminotransferases (Berger et al.,
1996). In Leishmania, TAT has also been proposed to be responsi-
ble for catalyzing this ﬁnal step based on the ability of the
enzyme to use KMTB as substrate (Marciano et al., 2009).This,
agrees with our data (see Section 3.4.). Therefore we aimed to
deﬁne the active sites that stabilize KMTB prior to its transamina-
tion by molecular dynamic simulations. As a result, we have
predicted the bonds formed for recognition of the transit state
involving KMTB and PMP pair, and we have generated a
pharmacophore model that will allow the identiﬁcation of novel
inhibitors in the treatment against leishmaniases. In the case of
LiTAT, most of the residues determined involved in the pharma-
cophore are clearly different to the correspondent ones described
for the mammalian enzyme. With the model generated, KMTB is
forming a hydrogen bond with PMP and there are electrostatic
interactions with His177 and a hydrophobic interaction with
Ala322. Interestingly, these residues are not present in the
mammalian orthologues suggesting that they may play an
important role in the selectivity of the substrates in LiTAT.
Fig. 5. The pharmacophore model was developed using the X-ray L. infantum
tyrosine aminotransferase structure. Amino acceptor group of KMTB is directed
towards amine group of PMP transit state (surrounded by red circle). Carbons,
oxygens, nitrogens, sulfurs and phosphates are shown by gray, red, blue, yellow and
orange respectively. Each sphere indicates the location tolerance of a particular
feature point. Hydrogen bonds, hydrophobic and electrostatic interactions are
shown by green, dark blue and cyan respectively. (For interpretation of the
references to colours in this ﬁgure legend, the reader is referred to the web version
of this paper.)
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The ﬁnal product of the tyrosine catabolic pathway, pHPL, is
excreted by L. infantum promastigotes. LiTAT is a cytoplasmic
protein over-expressed in the more infective L. infantum and in
resistant to nitric oxide L. chagasi promastigotes, as well as in
axenic amastigotes and, as a difference with the mammalian TAT,
is able to transaminate KMTB. The pharmacophore model devel-
oped in this study may be useful for the screening of new ligands
against LiTAT. For these reasons, this enzyme can be considered
as a candidate for the development of new drugs against
leishmaniasis.
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